Andrew K. Balo - Mar 10, 2023 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
EVP Regulatory Strategy Clinic
Signature
By: Jereme Sylvain For: Andrew K Balo
Stock symbol
DXCM
Transactions as of
Mar 10, 2023
Transactions value $
-$1,300,026
Form type
4
Date filed
3/14/2023, 04:45 PM
Previous filing
Mar 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Disposed to Issuer -$365K -3.28K -5.23% $111.40 59.3K Mar 10, 2023 Direct F1, F2
transaction DXCM Common Stock Disposed to Issuer -$268K -2.41K -4.06% $111.40 56.9K Mar 10, 2023 Direct F1, F2
transaction DXCM Common Stock Disposed to Issuer -$667K -5.99K -10.53% $111.40 50.9K Mar 10, 2023 Direct F1, F2
holding DXCM Common Stock 30.2K Mar 10, 2023 by Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Andrew K. Balo is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
F3 Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.